TY - JOUR
T1 - Expert meeting report
T2 - Towards a joint european roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy
AU - Golebski, Korneliusz
AU - Dankelman, Lente H.M.
AU - Björkander, Sofia
AU - Bønnelykke, Klaus
AU - Brinkman, Paul
AU - Deschildre, Antoine
AU - van Dijk, Yoni E.
AU - Fleming, Louise
AU - Grigg, Jonathan
AU - Hamelmann, Eckard
AU - Hashimoto, Simone
AU - Kabesch, Michael
AU - Klevebro, Susanna
AU - Maitland-Van der Zee, Anke Hilse
AU - Merid, Simon K.
AU - Nieto, Antonio
AU - Niggel, Jakob
AU - Nilsson, Caroline
AU - Potočnik, Uroš
AU - Roberts, Graham
AU - Rusconi, Franca
AU - Saglani, Sejal
AU - Valente, Elisangela
AU - van Drunen, Cornelis
AU - Wang, Gang
AU - Melén, Erik
AU - Vijverberg, Susanne J.H.
N1 - Funding Information:
Conflict of interest: K. Golebski received funds from STIMAG and from the Amsterdam Infection & Immunity Institute. L.H.M. Dankelman has nothing to disclose. S. Björkander has nothing to disclose. K. Bønnelykke has nothing to disclose. P. Brinkman has nothing to disclose. A. Deschildre has nothing to disclose. Y.E. van Dijk has nothing to disclose. L. Fleming reports grants from Asthma UK, and speakers fees or fees for expert consultation from Teva, AstraZeneca, Sanofi, Respiri and Novartis; all fees paid directly to her institution and outside the submitted work. J. Grigg reports personal fees from GSK, AstraZeneca and Novartis during the conduct of the study. E. Hamelmann has nothing to disclose. S. Hashimoto has nothing to disclose. M. Kabesch has nothing to disclose. S. Klevebro has nothing to disclose. A-H. Maitland-van der Zee has received research grants outside the submitted work from GSK, Boehringer Ingelheim and Vertex; she is the principal investigator of a P4O2 (Precision Medicine for more Oxygen) public–private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis); and she has served in advisory boards for AstraZeneca, GSK and Boehringer Ingelheim with money paid to her institution. S.K. Merid has nothing to disclose. A. Nieto reports grants and personal fees from Novartis outside the submitted work. J. Niggel has nothing to disclose. C. Nilsson has nothing to disclose. U. Potocnik reports grants from the Ministry of Education, Science and Sport. G. Roberts reports grants from the EU during the conduct of the study. F. Rusconi has nothing to disclose. S. Saglani has nothing to disclose. E. Valente has nothing to disclose. C. van Drunen has nothing to disclose. G. Wang has nothing to disclose. E. Melén reports personal fees from AstraZeneca, Chiesi, Novartis and Sanofi (advisory board activities) outside the submitted work. S.J.H. Vijverberg reports grants from ZonMW during the conduct of the study.
Funding Information:
Support statement: The PERMEABLE consortium is supported by ZonMW (project number: 456008004), the Swedish Research Council (project number 2018-05619), the Ministry of Education, Science and Sport of the Republic of Slovenia (contract number C3330-19-252012), and the German Ministry of Education and Research (BMBF) (project number FKZ01KU1909A), under the frame of the ERA PerMed JTC 2018 Call. Funding information for this article has been deposited with the Crossref Funder Registry.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - A digital multidisciplinary European expert meeting took place on the 9 July 2020 to identify the unmet needs of paediatric severe asthma patients, and set the priorities for clinical and research activities ahead https://bit.ly/3CeLBHB.
AB - A digital multidisciplinary European expert meeting took place on the 9 July 2020 to identify the unmet needs of paediatric severe asthma patients, and set the priorities for clinical and research activities ahead https://bit.ly/3CeLBHB.
UR - https://www.scopus.com/pages/publications/85121473501
U2 - 10.1183/23120541.00381-2021
DO - 10.1183/23120541.00381-2021
M3 - Editorial
C2 - 34729368
SN - 2312-0541
VL - 7
JO - ERJ open research
JF - ERJ open research
IS - 4
M1 - 00381-2021
ER -
SDG 3 Good Health and Well-being